Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10577374 | 0.97 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL27886724 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL472536 | 0.79 | CYP4F2 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28374111 | 0.77 | CYP4F2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL21986972 | 0.77 | CYP4F2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL16074757 | 0.77 | CYP4F2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22558017 | 0.77 | CYP4F2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28368582 | 0.77 | CYP4F2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| 1,4-Butanediol SCHEMBL9653088 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15183665 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285580-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | QLARIS BIO, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-3545958-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4384162-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | Qlaris Bio, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-115768419-A | Improved methods and compositions for the treatment of prodrugs of chromanccalin | 奎拉里斯生物公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023018958-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | QLARIS BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-4100003-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | Qlaris Bio, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387457-A1 | METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | QLARIS BIO, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2021158992-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | QLARIS BIO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20120238554-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2404604-A1 | Salts of potassium ATP channel openers and uses thereof | Essentialis, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1968601-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100256360-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7799777-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100028429-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-7572789-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028429-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20120238554-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20220387457-A1 | METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | CSNK1A1, CSNK1A1L, SI | SMN1; SMN2 2211/4885LMNA 1365/4885ALDH1A1 1548/4885 |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20100256360-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 697/4885LMNA 3009/4885ALDH1A1 891/4885 |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
| US-20240285580-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | KIT, CSNK1A1L, CSNK1G3 | SMN1; SMN2 668/4885LMNA 317/4885ALDH1A1 1569/4885 |
| US-20090148526-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | SMN1; SMN2 695/4885LMNA 3006/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.